Amlodipine Besylate/Irbesartan/Hydrochlorothiazide

苯磺酸氨氯地平/厄贝沙坦/氢氯噻嗪

Report date: 2026/03/30 17:02:26

Base Information

Drug NameAmlodipine Besylate/Irbesartan/Hydrochlorothiazide
Drug Alias NameN/A
ClassificationSmall molecules
Mechanisms of ActionVoltage-gated calcium channel blockersAngiotensin II Receptor Type 1 antagonistsThiazide-sensitive sodium-chloride cotransporter inhibitors
TargetsAngiotensin II Receptor Type 1Voltage-gated calcium channelThiazide-sensitive sodium-chloride cotransporter
Therapy Area/IndicationsHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2019/02/18
Country/TerritoryEU
CombinationsYes Amlodipine BesylateIrbesartanHydrochlorothiazide
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesWin Medica Sa
Inactive CompaniesN/A
Active IndicationsHypertension
Inactive IndicationsN/A

Other Information

ATC CodeC09DX
Related LinksN/A